New drug combo targets Hard-to-Treat cancers in Mid-Stage trial
NCT ID NCT07483554
First seen Mar 22, 2026 · Last updated Jun 23, 2026 · Updated 14 times
Summary
This Phase 2 study tests a new drug called IBI343 combined with two standard chemotherapies (gemcitabine and nab-paclitaxel) in about 389 people with advanced stomach or pancreatic cancers that have a specific protein (CLDN18.2). The main goals are to see if the combination shrinks tumors and to check for side effects. The trial is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI343 combined with gemcitabine and albumin-bound paclitaxel
What this could lead to
If successful, this could offer a new treatment option for people with advanced gastric or pancreatic cancers that have a specific marker (CLDN18.2).
What could go wrong
This is an early Phase 2 trial, so the combination may not work better than existing treatments. Side effects from the drugs could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.